Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. May 6, 2016; 7(2): 294-305
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294
Table 1 Studies included
Sample | Follow-up1 | Response | Adverse Events | Ref. | ||
Infection | Explant | Reoperation | ||||
61 | 13 | 0 | 1 | 2 | [60] | |
16 | 0 | 0 | 3 | [61] | ||
85 | 24 | 0 | 3 | 13 | [45] | |
39 | 12 | 2 | 2 | 2 | [62] | |
60 | 47 | 17 | 2 | 9 | 15 | [18] |
101 | 60 | 26 | 2 | 20 | 20 | [14] |
50 | 55.5 | 2 | 6 | 11 | [63] | |
42 | 0 | 2 | 5 | [64] | ||
23 | 114 | 2 | 3 | 5 | [65] | |
101 | 62 | 1 | 10 | 39 | [66] | |
37 | 17 | 27 | 0 | 0 | 3 | [50] |
41 | 51 | 0 | 0 | 6 | [67] | |
34 | 24 | 83 | 1 | 2 | 4 | [19] |
37 | 6 | 3 | 5 | 5 | [68] | |
58 | 74 | 37 | 0 | 6 | 15 | [49] |
12 | 117 | 0 | 3 | 14 | [69] | |
29 | 34 | 0 | 0 | 0 | [70] | |
7 | 32 | 1 | 1 | 2 | [71] | |
53 | 12 | 0 | 0 | 0 | [72] | |
10 | 0 | 0 | 1 | [73] | ||
29 | 35 | 2 | 2 | 8 | [74] | |
37 | 13 | 2 | 4 | 10 | [75] | |
14 | 6 | 0 | 0 | 0 | [76] | |
87 | 48.5 | 4 | 12 | 36 | [77] | |
40 | 3 | 3 | 7 | [78] | ||
15 | 6 | 10 | 0 | 0 | 0 | [47] |
85 | 12 | 31 | 0 | 1 | 1 | [54] |
145 | 12 | 137 | 5 | 6 | 15 | [6] |
29 | 0 | 1 | 1 | [79] | ||
27 | 10.7 | 3 | 1 | 4 | [80] | |
9 | 12 | 0 | 0 | 1 | [81] | |
120 | 60 | 90 | 12 | 30 | 72 | [8] |
57 | 63 | 2 | 6 | 12 | [82] | |
8 | 0 | 0 | 1 | [83] | ||
18 | 17 | 2 | 3 | 4 | [84] | |
50 | 74 | 4 | 11 | 24 | [85] | |
11 | 14 | 6 | 0 | 1 | 1 | [51] |
55 | 37 | 1 | 1 | 11 | [16] | |
23 | 38 | 0 | 0 | 4 | [15] | |
32 | 33 | 3 | 7 | 10 | [17] | |
53 | 12 | 0 | 0 | 0 | [7] | |
50 | 12 | 2 | 4 | 10 | [86] | |
10 | 29.5 | 10 | 2 | 8 | 8 | [53] |
33 | 27 | 0 | 5 | 11 | [87] | |
16 | 15.5 | 0 | 0 | 0 | [88] |
Table 2 Reported problems based on classification of adverse effects
Reported problem | Injury (n = 228) | Malfunction (n = 424) | P value |
Battery depletion | 9 | 6 | 0.057 |
Generator displacement | 11 | 5 | 0.007 |
Pocket erosion | 9 | 0 | < 0.001 |
Infection | 21 | 0 | < 0.001 |
Pain | 41 | 102 | 0.091 |
Lack of benefit | 70 | 243 | < 0.001 |
Lead problems | 40 | 30 | < 0.001 |
Other | 27 | 9 |
Table 3 Relationship between common primary and secondary concerns
Primary concern | No. of reports | Secondary concern |
Lack of benefit | 74 | Battery depletion: n = 2 Generator displacement: n = 3 Electromagnetic interference: n = 7 Lead problem: n = 3 Pain: n = 43 Programming problems: n = 14 Other: n = 2 |
Pain or discomfort | 32 | Generator displacement: n = 1 Electromagnetic interference: n = 8 Lack of benefit: n = 11 Lead problem: n = 1 Pain (second type): n = 4 Programming problems: n = 5 Other: n = 2 |
Pocket site complications | 8 | Lack of benefit: n = 1 Lead problem: n = 2 Pain: n = 5 |
Lead problem | 5 | Generator displacement: n = 1 Lack of benefit: n = 3 Pain: n = 1 |
Programming problem | 4 | Electromagnetic interference: n = 2 Lack of benefit: n = 1 Pain: n = 1 |
Table 4 Reported interventions based on patient problems
Primary concern | Sample | Conservative therapy | Operative therapy |
Lack of benefit | 325 | Stimulation adjusted: 160 Medication: 3 System check: 7 | Explant: 22 Replacement: 17 Pocket revision: 3 |
Pain or discomfort | 97 | Stimulation adjusted: 34 Medication: 4 System check: 2 | Explant: 8 Replacement: 1 Pocket revision: 7 |
Lead problem | 70 | Stimulation adjusted: 3 System check: 2 | Explant: 1 Replacement: 36 |
Programming problems | 30 | Stimulation adjusted: 11 | Replacement: 1 |
- Citation: Bielefeldt K. Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration. World J Gastrointest Pharmacol Ther 2016; 7(2): 294-305
- URL: https://www.wjgnet.com/2150-5349/full/v7/i2/294.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i2.294